This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loiseau, P. M.
Right arrow Articles by De Miguel, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loiseau, P. M.
Right arrow Articles by De Miguel, I.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2002, p. 1597-1601, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1597-1601.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Design and Antileishmanial Activity of Amphotericin B-Loaded Stable Ionic Amphiphile Biovector Formulations

P. M. Loiseau,1* L. Imbertie,2 C. Bories,1 D. Betbeder,2 and I. De Miguel2

LBCOP, UPRES 398-IFR 75, Faculté de Pharmacie, Université de Paris XI, 92290 Chatenay-Malabry Cedex,1 Biovector Therapeutics S. A., Chemin du Chêne Vert, 31676 Labège Cedex, France2

Received 18 October 2001/ Returned for modification 4 December 2001/ Accepted 4 February 2002

A new delivery system, Ionic Amphiphilic Biovector (ABV), comprised of anionic lipids (dipalmitoyl phosphatidyl glycerol) included in a cationic cross-linked polysaccharide matrix was used as a reservoir for amphotericin B (AmB). Two ABV formulations exhibited an in vitro and in vivo efficacy similar to commercial AmBisome against Leishmania donovani-infected mice. The higher stability of these ABV formulations indicates their potential for further development and applications.

* Corresponding author. Mailing address: LBCOP, UPRES 398-IFR75, Faculté de Pharmacie, Université de Paris XI, 92290 Chatenay-Malabry Cedex, France. Phone: 33 1 46 83 55 53. Fax: 33 1 46 83 55 57. E-mail: philippe.loiseau{at}cep.u-psud.fr.

Antimicrobial Agents and Chemotherapy, May 2002, p. 1597-1601, Vol. 46, No. 5
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.5.1597-1601.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nakayama, H., Loiseau, P. M., Bories, C., Torres de Ortiz, S., Schinini, A., Serna, E., Rojas de Arias, A., Fakhfakh, M. A., Franck, X., Figadere, B., Hocquemiller, R., Fournet, A. (2005). Efficacy of Orally Administered 2-Substituted Quinolines in Experimental Murine Cutaneous and Visceral Leishmaniases. Antimicrob. Agents Chemother. 49: 4950-4956 [Abstract] [Full Text]  
  • Al-Mohammed, H. I., Chance, M. L., Bates, P. A. (2005). Production and Characterization of Stable Amphotericin-Resistant Amastigotes and Promastigotes of Leishmania mexicana. Antimicrob. Agents Chemother. 49: 3274-3280 [Abstract] [Full Text]  
  • Larabi, M., Yardley, V., Loiseau, P. M., Appel, M., Legrand, P., Gulik, A., Bories, C., Croft, S. L., Barratt, G. (2003). Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B. Antimicrob. Agents Chemother. 47: 3774-3779 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»